Article metrics

Download PDFPDF

A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

 

Online download statistics by month:

Online download statistics by month: February 2019 to June 2024

AbstractFullPdf
Feb 201914281413127
Mar 201923222753
Apr 201913212928
May 201911310637
Jun 2019565022
Jul 2019434119
Aug 20191754714
Oct 20191544019
Nov 20191733917
Dec 20191904210
Jan 20202525520
Feb 202032213726
Mar 202022611430
May 20201323620
Jun 2020625445
Jul 2020665321
Aug 202056487
Sep 202016915433
Oct 202020920121
Nov 2020624218
Dec 202016814827
Jan 2021836124
Feb 2021927435
Mar 2021795725
Apr 2021696327
May 2021705228
Jun 2021735124
Jul 2021716623
Aug 2021665924
Sep 2021685226
Oct 20211017242
Nov 2021553635
Dec 2021544410
Jan 2022858629
Feb 2022463613
Mar 2022705319
Apr 2022754410
May 2022654725
Jun 2022715019
Jul 2022895523
Aug 2022675719
Sep 2022695020
Oct 20221297222
Nov 2022584415
Dec 2022655521
Jan 2023614316
Feb 2023614726
Mar 2023736217
Apr 2023483814
May 2023533721
Jun 202335328
Jul 2023787031
Aug 2023493915
Sep 2023574116
Oct 2023613819
Nov 2023695429
Dec 2023633923
Jan 2024594319
Feb 2024412416
Mar 2024372535
Apr 2024715569
May 2024513317
Jun 202428237
Total718552551570